

Glioblastoma Multiforme Treatment-North America Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/GB0AE8D6087EN.html

Date: January 2018

Pages: 132

Price: US\$ 3,480.00 (Single User License)

ID: GB0AE8D6087EN

Abstracts

Report Summary

Glioblastoma Multiforme Treatment-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Glioblastoma Multiforme Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Glioblastoma Multiforme Treatment 2013-2017, and development forecast 2018-2023

Main market players of Glioblastoma Multiforme Treatment in North America, with company and product introduction, position in the Glioblastoma Multiforme Treatment market

Market status and development trend of Glioblastoma Multiforme Treatment by types and applications

Cost and profit status of Glioblastoma Multiforme Treatment, and marketing status Market growth drivers and challenges

The report segments the North America Glioblastoma Multiforme Treatment market as:

North America Glioblastoma Multiforme Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States



Canada

Mexico

North America Glioblastoma Multiforme Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Bevacizumab (Avastin)
Temozolomide (Temodar and Temodal and Temcad)
Carmustine (BiCNU)

North America Glioblastoma Multiforme Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

North America Glioblastoma Multiforme Treatment Market: Players Segment Analysis (Company and Product introduction, Glioblastoma Multiforme Treatment Sales Volume, Revenue, Price and Gross Margin):

AbbVie, Inc
Activartis GmbH
Agenus Inc
Arog Pharmaceuticals, Inc
Bristol-Myers Squibb Company
Cavion LLC
Celldex Therapeutics Inc
Cortice Biosciences
Exelixis Inc

F. Hoffmann-La Roche Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF GLIOBLASTOMA MULTIFORME TREATMENT

- 1.1 Definition of Glioblastoma Multiforme Treatment in This Report
- 1.2 Commercial Types of Glioblastoma Multiforme Treatment
 - 1.2.1 Bevacizumab (Avastin)
 - 1.2.2 Temozolomide (Temodar and Temodal and Temcad)
 - 1.2.3 Carmustine (BiCNU)
- 1.3 Downstream Application of Glioblastoma Multiforme Treatment
 - 1.3.1 Hospital
 - 1.3.2 Clinic
- 1.4 Development History of Glioblastoma Multiforme Treatment
- 1.5 Market Status and Trend of Glioblastoma Multiforme Treatment 2013-2023
- 1.5.1 North America Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023
- 1.5.2 Regional Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Glioblastoma Multiforme Treatment in North America 2013-2017
- 2.2 Consumption Market of Glioblastoma Multiforme Treatment in North America by Regions
- 2.2.1 Consumption Volume of Glioblastoma Multiforme Treatment in North America by Regions
- 2.2.2 Revenue of Glioblastoma Multiforme Treatment in North America by Regions
- 2.3 Market Analysis of Glioblastoma Multiforme Treatment in North America by Regions
- 2.3.1 Market Analysis of Glioblastoma Multiforme Treatment in United States 2013-2017
 - 2.3.2 Market Analysis of Glioblastoma Multiforme Treatment in Canada 2013-2017
- 2.3.3 Market Analysis of Glioblastoma Multiforme Treatment in Mexico 2013-2017
- 2.4 Market Development Forecast of Glioblastoma Multiforme Treatment in North America 2018-2023
- 2.4.1 Market Development Forecast of Glioblastoma Multiforme Treatment in North America 2018-2023
- 2.4.2 Market Development Forecast of Glioblastoma Multiforme Treatment by Regions 2018-2023



CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole North America Market Status by Types
- 3.1.1 Consumption Volume of Glioblastoma Multiforme Treatment in North America by Types
- 3.1.2 Revenue of Glioblastoma Multiforme Treatment in North America by Types
- 3.2 North America Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in United States
 - 3.2.2 Market Status by Types in Canada
 - 3.2.3 Market Status by Types in Mexico
- 3.3 Market Forecast of Glioblastoma Multiforme Treatment in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Glioblastoma Multiforme Treatment in North America by Downstream Industry
- 4.2 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in United States
- 4.2.2 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Canada
- 4.2.3 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Mexico
- 4.3 Market Forecast of Glioblastoma Multiforme Treatment in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 5.1 North America Economy Situation and Trend Overview
- 5.2 Glioblastoma Multiforme Treatment Downstream Industry Situation and Trend Overview

CHAPTER 6 GLIOBLASTOMA MULTIFORME TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Glioblastoma Multiforme Treatment in North America by Major



Players

- 6.2 Revenue of Glioblastoma Multiforme Treatment in North America by Major Players
- 6.3 Basic Information of Glioblastoma Multiforme Treatment by Major Players
- 6.3.1 Headquarters Location and Established Time of Glioblastoma Multiforme Treatment Major Players
- 6.3.2 Employees and Revenue Level of Glioblastoma Multiforme Treatment Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 GLIOBLASTOMA MULTIFORME TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 AbbVie, Inc
 - 7.1.1 Company profile
 - 7.1.2 Representative Glioblastoma Multiforme Treatment Product
- 7.1.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of AbbVie, Inc
- 7.2 Activartis GmbH
 - 7.2.1 Company profile
 - 7.2.2 Representative Glioblastoma Multiforme Treatment Product
- 7.2.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Activartis GmbH
- 7.3 Agenus Inc
 - 7.3.1 Company profile
 - 7.3.2 Representative Glioblastoma Multiforme Treatment Product
- 7.3.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Agenus Inc
- 7.4 Arog Pharmaceuticals, Inc
 - 7.4.1 Company profile
 - 7.4.2 Representative Glioblastoma Multiforme Treatment Product
- 7.4.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Arog Pharmaceuticals, Inc
- 7.5 Bristol-Myers Squibb Company
 - 7.5.1 Company profile
 - 7.5.2 Representative Glioblastoma Multiforme Treatment Product
 - 7.5.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of



Bristol-Myers Squibb Company

- 7.6 Cavion LLC
 - 7.6.1 Company profile
 - 7.6.2 Representative Glioblastoma Multiforme Treatment Product
- 7.6.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cavion LLC
- 7.7 Celldex Therapeutics Inc
 - 7.7.1 Company profile
- 7.7.2 Representative Glioblastoma Multiforme Treatment Product
- 7.7.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Celldex Therapeutics Inc
- 7.8 Cortice Biosciences
 - 7.8.1 Company profile
 - 7.8.2 Representative Glioblastoma Multiforme Treatment Product
- 7.8.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cortice Biosciences
- 7.9 Exelixis Inc
 - 7.9.1 Company profile
 - 7.9.2 Representative Glioblastoma Multiforme Treatment Product
- 7.9.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Exelixis Inc
- 7.10 F. Hoffmann-La Roche Ltd
 - 7.10.1 Company profile
- 7.10.2 Representative Glioblastoma Multiforme Treatment Product
- 7.10.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of
- F. Hoffmann-La Roche Ltd

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 8.1 Industry Chain of Glioblastoma Multiforme Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 9.1 Cost Structure Analysis of Glioblastoma Multiforme Treatment
- 9.2 Raw Materials Cost Analysis of Glioblastoma Multiforme Treatment



- 9.3 Labor Cost Analysis of Glioblastoma Multiforme Treatment
- 9.4 Manufacturing Expenses Analysis of Glioblastoma Multiforme Treatment

CHAPTER 10 MARKETING STATUS ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Glioblastoma Multiforme Treatment-North America Market Status and Trend Report

2013-2023

Product link: https://marketpublishers.com/r/GB0AE8D6087EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB0AE8D6087EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



